Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Bria

Showing results (131-140 of 377) with videos related to

Pageof 38
Sort By:
Oncology|July 16, 2005
Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II studyCecilia Nisticò, Francesco Cognetti, Luciano Frontini, et al.
Critical Reviews in Oncology/Hematology|June 6, 2022
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trialsAlice Avancini, Isabella Sperduti, Anita Borsati, et al.
Internal and Emergency Medicine|December 18, 2020
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysisEmanuele Rinninella, Marco Cintoni, Pauline Raoul, et al.
Cancers|May 14, 2020
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future PerspectivesMiriam Grazia Ferrara, Vincenzo Di Noia, Ettore D'Argento, et al.
Critical Reviews in Oncology/Hematology|December 17, 2013
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trialsSara Pilotto, Massimo Di Maio, Umberto Peretti, et al.
Cancer|June 20, 2007
Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trialsEmilio Bria, Michele Milella, Alain Gelibter, et al.
Anti-Cancer Drugs|December 13, 2006
Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin-paclitaxel in metastatic breast cancer patientsCecilia Nisticò, Emilio Bria, Federica Cuppone, et al.
Geriatrics (Basel, Switzerland)|October 26, 2022
Safety and Efficacy of a First-Line Chemotherapy Tailored by G8 Score in Elderly Metastatic or Locally Advanced Gastric and Gastro-Esophageal Cancer Patients: A Real-World AnalysisIna Valeria Zurlo, Carmelo Pozzo, Antonia Strippoli, et al.
Seminars in Oncology|October 2, 2022
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysisLorenzo Belluomini, Sara Pilotto, Alice Avancini, et al.
Oncology|February 28, 2009
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancersMaria S Pino, Michele Milella, Alain Gelibter, et al.
Pageof 38

Showing results (131-140 of 377) with videos related to

Sort By:
Pageof 38
Oncology|July 16, 2005
Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II studyCecilia Nisticò, Francesco Cognetti, Luciano Frontini, et al.
Critical Reviews in Oncology/Hematology|June 6, 2022
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trialsAlice Avancini, Isabella Sperduti, Anita Borsati, et al.
Internal and Emergency Medicine|December 18, 2020
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysisEmanuele Rinninella, Marco Cintoni, Pauline Raoul, et al.
Cancers|May 14, 2020
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future PerspectivesMiriam Grazia Ferrara, Vincenzo Di Noia, Ettore D'Argento, et al.
Critical Reviews in Oncology/Hematology|December 17, 2013
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trialsSara Pilotto, Massimo Di Maio, Umberto Peretti, et al.
Cancer|June 20, 2007
Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trialsEmilio Bria, Michele Milella, Alain Gelibter, et al.
Anti-Cancer Drugs|December 13, 2006
Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin-paclitaxel in metastatic breast cancer patientsCecilia Nisticò, Emilio Bria, Federica Cuppone, et al.
Geriatrics (Basel, Switzerland)|October 26, 2022
Safety and Efficacy of a First-Line Chemotherapy Tailored by G8 Score in Elderly Metastatic or Locally Advanced Gastric and Gastro-Esophageal Cancer Patients: A Real-World AnalysisIna Valeria Zurlo, Carmelo Pozzo, Antonia Strippoli, et al.
Seminars in Oncology|October 2, 2022
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysisLorenzo Belluomini, Sara Pilotto, Alice Avancini, et al.
Oncology|February 28, 2009
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancersMaria S Pino, Michele Milella, Alain Gelibter, et al.
Pageof 38